

IL1F10(?-152) binds IL1RAPL1

Mora, J., Varusai, TM.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

18/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

IL1F10(?-152) binds IL1RAPL1 ↗

Stable identifier: R-HSA-9008052

Type: binding

Compartments: extracellular region, plasma membrane



Interleukins are immunomodulatory proteins that elicit a wide array of responses in cells and tissues. Interleukin 1 family member 10 (IL1F10, IL 38) is a member of the IL1 family (Lin et al. 2001, Bensen et al. 2001). IL1F10 is selectively produced by human apoptotic cells (Mora et al. 2016) and human epidermal keratinocytes (based on mRNA studies) (Boutet M A et al. 2016). IL1F10 can bind to interleukin 1 receptor like 2 (IL1RL2) and may result in the suppression of IL 17 and IL 22 and induction of IL 6 production (van de Veerdonk et al. 2012, Mora et al. 2016). IL1F10 is synthesized as precursors that require N terminal processing to attain full receptor agonist or antagonist function (Mora et al. 2016). Both full length (1 – 152 amino acids) and N terminal truncated (20 – 152 amino acids) IL1F10 can bind Interleukin 1 receptor accessory protein like 1 (IL1RAPL1) (Mora et al. 2016). The binding affinity of truncated IL1F10 is much higher than that of the full length. However, binding of the full length or truncated forms has distinct outcomes; the former induces IL6 and the latter suppresses IL6 via JNK and AP1 signaling (Mora et al. 2016).

Literature references

Weigert, A., Putyrski, M., Frank, AC., Wittig, I., Brüne, B., Schlemmer, A. et al. (2016). Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. *J Mol Cell Biol.* ↗

Editions

2017-07-21	Authored, Edited	Varusai, TM.
2017-07-28	Reviewed	Mora, J.